EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance

Kevin Holm, Neil A Bhowmick

Journal of Clinical Investigation · 16.11.2026 · 136 (22)

DOI: 10.1172/jci210677 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.11.2026. Verfasst von Kevin Holm und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Serotonin, Tryptophan Hydroxylase, Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced prostate cancer frequently escapes androgen receptor pathway inhibition through mechanisms including restored androgen signaling, lineage plasticity, and metabolic adaptation. Neuroendocrine prostate cancer (NEPC) can emerge as an androgen-insensitive lineage and has mostly been studied in the context of its transcriptional and epigenetic reprogramming. However, evidence increasingly supports the requirement for metabolic rewiring across a variety of pathways in the transition to NEPC. In this issue of the JCI , Wei et al. demonstrated that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) stabilizes the plastic state of NEPC by supporting serotonin-based posttranslational modification (serotonylation) of mTOR and FOXM1/E2F1 activation. These findings position TPH1 as both a neuroendocrine marker and a functional mediator of hormone therapy resistance. Because metabolic escape can involve many pathways, biomarker-guided patient selection will be required for translating these findings to an intervention. Accordingly, targeting TPH1 may delay or reverse therapy-induced NEPC in selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SerotoninTryptophan HydroxylaseDrug Resistance, NeoplasmProstatic NeoplasmsNeoplasm ProteinsHumansMaleAnimalsTOR Serine-Threonine Kinases

Substanzen

SerotoninTryptophan HydroxylaseTPH1 protein, humanTOR Serine-Threonine KinasesNeoplasm Proteins

Förderung

  • NCI NIH HHS

Zitieren

APA

Holm, K., & Bhowmick, N. A. (2026). Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance. Journal of Clinical Investigation, 136(22). https://doi.org/10.1172/jci210677

Vancouver

Holm K, Bhowmick NA. Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance. Journal of Clinical Investigation. 2026;136(22). doi:10.1172/jci210677

BibTeX
@article{Holm2026,
  author = {Holm, Kevin and Bhowmick, Neil A},
  title = {Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {22},
  doi = {10.1172/jci210677}
}
Kostenlos starten →